Searchable abstracts of presentations at key conferences in endocrinology

Endocrine Abstracts

Published by BioScientifica

Page 1 of about 4 results

ea0099p299 | Diabetes, Obesity, Metabolism and Nutrition | ECE2024

Effectiveness of dapagliflozin and sitagliptin fixed dose combination in indian patients with type 2 diabetes mellitus in real world settings: age stratified-analysis from a retrospective study

Agrawala Ritesh , Bhattacharyya Supratik , Bharathi B Prakadeesh , Kudrigikar Vinay , Ahire Prachi , Dharmadhikari Shruti , Khandhedia Chintan , Markandeywar Neeraj , Mane Amey , Mehta Suyog

Introduction and Objective: Incidence of type 2 diabetes mellitus (T2D) is rapidly increasing resulting in significant metabolic disorders and complications. Dapagliflozin and sitagliptin have complimentary mechanism of action and have shown synergistic effects in controlling blood glucose levels with advantage of low risk of hypoglycemia. Use of fixed dose combinations (FDC) is associated with improved patient compliance. This is an Age Stratified analysis of electronic medic...
5 shares

ea0099ep639 | Diabetes, Obesity, Metabolism and Nutrition | ECE2024

Real-world effectiveness of dapagliflozin and sitagliptin fixed-dose combination in indian patients with type 2 diabetes: a retrospective analysis of electronic medical records stratified by BMI

Kovil Rajiv , Deshmane Rajesh , Bharathi B Prakadeesh , Ahire Prachi , Kudrigikar Vinay , Dharmadhikari Shruti , Khandhedia Chintan , Markandeywar Neeraj , Mane Amey , Mehta Suyog

Introduction and Objective: Escalating prevalence of type 2 diabetes mellitus (T2D) in India presents a significant health challenge. Dapagliflozin and sitagliptin are important treatments for achieving glycaemic control in patients with T2D. Dapagliflozin promotes weight loss benefiting overweight and obese patients, while sitagliptin enhances incretin hormone activity with modest weight loss. This is a BMI-stratified analysis of electronic medical record (EMR) based real wor...
2 shares

ea0099p471 | Diabetes, Obesity, Metabolism and Nutrition | ECE2024

Subgroup analysis of phase 3 study of fixed-dose combination of dapagliflozin, glimepiride and metformin IR in type 2 diabetes mellitus patients with HbA1c 9%-11%

Kurmi Prakash , Singh Manish , Gupta Vishal , Siddegowda Chikkalingaiah , Shukla Jitendra , Gofne Sandip , Lomte Nilesh , Shendkar Kaustubh , Gangwani Dinesh , Kumar Surendra , Gupta Sandeep , G Nagarajaiah Aravind , Bhaskar Amit , Sharma Prabhat , Baidya Arjun , Maiti Animesh , Gowda Ambana , Ambaliya Jayesh , Giriappa K Balachandra , Mahavar Sunil , Gupta Hemant , Mandodari Rajurkar Dr , Sonowal Supriya , Patel Piyush , Patil Dipak , Lakhwani Lalit , Ghadge Pravin , Mehta Suyog , Joglekar Sadhna

Background and Objective: Fixed-dose combination (FDC) of dapagliflozin+metformin+sulfonylurea with complementary mechanisms can provide effective glycaemic control, preserve beta-cell function, improved compliance without risk of weight gain, and reno-protective action in type 2 diabetes mellitus (T2DM) patients. This subgroup analysis aimed to assess efficacy and safety of triple-drug FDC versus (vs) two-drug combination in T2DM Indian patients with HbA1c 9%-11%.<p class...
7 shares

ea0099ep337 | Diabetes, Obesity, Metabolism and Nutrition | ECE2024

Subgroup analysis of phase 3 study of fixed-dose combination of dapagliflozin, glimepiride and metformin IR in type 2 diabetes mellitus patients aged <45 years and 45 to 65 years

Kurmi Prakash , Singh Manish , Gupta Vishal , Siddegowda Chikkalingaiah , Shukla Jitendra , Gofne Sandip , Lomte Nilesh , Shendkar Kaustubh , Gangwani Dinesh , Kumar Surendra , Gupta Sandeep , G Nagarajaiah Aravind , Bhaskar Amit , Sharma Prabhat , Baidya Arjun , Maiti Animesh , Gowda Ambana , Ambaliya Jayesh , Giriappa K Balachandra , Mahavar Sunil , Gupta Hemant , Rajurkar Mandodari , Sonowal Supriya , Patel Piyush , Patil Dipak , Lakhwani Lalit , Ghadge Pravin , Mehta Suyog , Joglekar Sadhna

Background and Objective: Fixed-dose combination (FDC) of dapagliflozin+metformin+sulfonylurea with complementary mechanisms can provide effective glycaemic control, preserve beta-cell function, improved compliance without risk of weight gain, and reno-protective action in type 2 diabetes mellitus (T2DM) patients. This subgroup analysis assessed efficacy and safety of triple-drug FDC vs (vs) two-drug combination in T2DM Indian patients aged <45 years and 45-65 years.<p...
5 shares

Published by BioScientifica

Endocrine Abstracts
ISSN 1470-3947 (print) | ISSN 1479-6848 (online)
© Bioscientifica 2024 | Privacy policy | Cookie settings

BiosciAbstracts

Bioscientifica Abstracts is the gateway to a series of products that provide a permanent, citable record of abstracts for biomedical and life science conferences.

Find out more